| Income Statement | 2025-09-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net expenses related to opko collaboration agreement | 3,256 | 3,021 | 2,174 | |
| Operating loss | -3,256 | -3,021 | -2,165 | |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | -3,021 | - | |
| Financial income, net | 56 | - | 20 | |
| Net loss | -3,200 | -3,021 | -2,145 | |
| Earnings per share, basic and diluted | 0.07 | 0.08 | 0.06 | |
| Earnings per share, diluted | 0.07 | 0.08 | 0.06 | |
| Weighted average number of shares outstanding, basic and diluted | 47,089,814 | 37,644,612 | 37,090,160 | |
| Weighted average number of shares outstanding, diluted | 47,089,814 | 37,644,612 | 37,090,160 | |
Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX)